6 Result: Amgen
Amgen Posts Mixed Results; Repligen Beats Estimates
October 31st, 2023
Amgen Inc. (Nasdaq: AMGN), a global biotechnology company, posted third-quarter 2023 earnings per share (EPS) of $4.96, surpassing the consensus EPS estimate of $4.66. The company's quarterly revenues stood at $6.90 billion, slightly below analysts' . Read more
Breaking Biotech Newsflash: Amgen, Gilead Sciences, and Merck
September 10th, 2023
Amgen Inc. (Nasdaq: AMGN) unveiled encouraging data from the CodeBreaK 101 clinical trial, showcasing the effectiveness of LUMAKRAS (sotorasib) plus chemotherapy (carboplatin and pemetrexed) in treating KRAS G12C-mutated advanced non-small cell lung . Read more
Biopharmaceutical Giant Amgen to Settle FTC and State Challenges to its Horizon Therapeutics Acquisition
September 01st, 2023
Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products Washington D.C. / CRWE PRESS RELEASE / September 1, 2023 - The Federal Tra. Read more
FTC Takes Legal Action to Halt Amgen's Acquisition of Horizon Therapeutics Amid Monopoly Concerns, Applied Digital Secures Major AI Customer, Etsy Faces Price Target Revision
May 16th, 2023
The Federal Trade Commission (FTC) has taken action to prevent the acquisition of Horizon Therapeutics plc (Nasdaq: HZNP) by the biopharmaceutical giant, Amgen Inc. (Nasdaq: AMGN). In its efforts to block the transaction, the FTC has filed a lawsuit . Read more
FTC Sues to Block Biopharmaceutical Giant Amgen from Acquisition That Would Entrench Monopoly Drugs Used to Treat Two Serious Illnesses
May 16th, 2023
The $27.8 billion acquisition of Horizon Therapeutics plc would enable Amgen Inc. to stifle competition for thyroid eye disease and chronic refractory gout treatments, the agency says LAS VEGAS, NV / CRWE PRESS RELEASE / May 16, 2023 - The F. Read more
Ensysce Biosciences Announces Successful Completion of Clinical Study for Pain Medication with Overdose Protection, Amgen and TScan Therapeutics Collaborate to Identify Antigens for Crohn's Disease Treatment
May 09th, 2023
Ensysce Biosciences, Inc. (Nasdaq: ENSC) has completed the clinical study of its first pain medication with overdose protection, PF614-MPAR, known as PF614-MPAR-101. The final Part B of the study showed that PF614-MPAR effectively reduced opioid deli. Read more
Want To Find Some News?
News By Industries
Recent Post
-
CSX, VinFast Auto, and Crown Castle's Earnings Preview
April 14th, 2024Earnings Spotlight: McCormick, TD SYNNEX, and GameStop Set to Report
March 23rd, 2024Upcoming Earnings: Adobe, Ulta Beauty, and Smartsheet Under the Lens
March 10th, 2024
Member Login